Key Takeaways
- CNBC’s Jim Cramer cautioned against purchasing stocks experiencing “parabolic” rallies in tech and artificial intelligence sectors
- The Mad Money host believes superior investment opportunities lie in undervalued, neglected equities
- His Charitable Trust purchased Johnson & Johnson stock during its recent decline
- Cramer named J&J his top pharmaceutical pick for 2026, surpassing Eli Lilly, due to its development pipeline and corporate restructuring
- The investing veteran emphasized maintaining balanced exposure between momentum and value stocks
During Monday’s broadcast of CNBC’s Mad Money, Jim Cramer delivered a contrarian message: avoid the market’s hottest performers and focus on what the crowd is abandoning.
According to Cramer, equities experiencing “parabolic” price action—particularly within technology and artificial intelligence—present significant risk for buyers. He admitted that purchasing stocks during such explosive moves has typically resulted in losses for him.
“Those are all too hot, hot, hot for me,” Cramer stated, addressing the surging semiconductor and AI sector stocks.
Rather than pursuing momentum names like Intel or Advanced Micro Devices, Cramer revealed he’s taking the opposite approach. His strategy involves accumulating shares of high-quality businesses that have experienced selloffs and lost market favor.
His CNBC Investing Club Charitable Trust recently purchased Johnson & Johnson shares during the stock’s descent. The healthcare sector currently ranks as the S&P 500’s worst performer year-to-date.
“We are buying it in freefall,” Cramer explained. “You don’t get to buy the best at a discount very often. When you do, you buy some.”
Cramer’s Rationale Behind the Johnson & Johnson Investment
Cramer declared that Johnson & Johnson has become his preferred pharmaceutical investment, displacing Eli Lilly from that position. His conviction stems from the company’s robust drug pipeline and its strategic business transformation initiatives.
The healthcare giant has been divesting underperforming business units while intensifying its focus on pharmaceutical research and development. The company boasts numerous drug candidates in advanced clinical trials and has secured several recent regulatory approvals.
According to Cramer, the stock’s recent weakness stems primarily from market noise, especially litigation concerns related to talc products. He contends these worries have eclipsed the substantial operational progress occurring within the organization.
Cramer also identified a recurring pattern surrounding Johnson & Johnson’s earnings releases. The stock frequently experiences selling pressure immediately after results are published in the morning, only to rebound once management’s conference call commences. “If it gets blasted, try to get some,” he advised.
Building a Balanced Portfolio Strategy
Cramer’s overarching message centered on portfolio construction methodology. He warned that concentrating exclusively in the market’s hottest sectors creates unnecessary vulnerability since investor sentiment can reverse abruptly.
“Your portfolio always needs to have a decent mix between what’s hot and what’s not,” he emphasized.
When specific market segments lose momentum, maintaining positions in undervalued companies ensures continued portfolio performance. Cramer credited this philosophy to lessons learned during his time at Goldman Sachs.
“They don’t all go up at once. To which I always said, but something should go up.”
Healthcare equities have faced substantial headwinds throughout 2025. Johnson & Johnson shares have declined over the trailing twelve months, with the stock dropping approximately 1.57% in recent trading sessions amid persistent sector-wide weakness.
